Large-Scale Oligonucleotide Synthesis Service Market Report: Trends, Forecast and Competitive Analysis to 2031

Large-Scale Oligonucleotide Synthesis Service Market Trends and Forecast

The future of the global large-scale oligonucleotide synthesis service market looks promising with opportunities in the biotech company and academic scientific research institution markets. The global large-scale oligonucleotide synthesis service market is expected to grow with a CAGR of 6.8% from 2025 to 2031. The major drivers for this market are the rising demand for personalized medicine, the growing applications in diagnostics & therapeutics, and the increasing investments in research & development.

• Lucintel forecasts that, within the type category, modified primer synthesis is expected to witness higher growth over the forecast period.

• Within the application category, biotech company is expected to witness higher growth.

• In terms of region, North America is expected to witness the highest growth over the forecast period. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Large-Scale Oligonucleotide Synthesis Service Market

The large-scale oligonucleotide synthesis service market is experiencing immense change fueled by the growing need for therapeutic oligonucleotides and the demand for effective and affordable manufacturing solutions.

• Continuous Flow Synthesis for Increased Scale and Efficiency: Conventional batch wise synthesis techniques are limited in scale. Continuous flow synthesis, in which reagents are pumped continuously through a reactor, is a major trend towards obtaining higher scales, greater yields, and better cost effectiveness in oligonucleotide production for therapeutic purposes.

• Advanced Purification Technologies Development: Cost effective and efficient large scale oligonucleotide batch purification to satisfy rigorous purity needs is essential. Future trends involve the development and deployment of novel chromatographic methods, membrane separation technologies, and other novel purification processes to eliminate synthesis byproducts and impurities.

• Automation and Digitalization Integration: To increase efficiency, minimize manual errors, and provide process consistency in large scale oligonucleotide production, there is increasing movement towards integrating advanced automation systems and digital data management platforms across the synthesis and purification processes.

• Sustainable and Environmentally Friendly Manufacturing: The pharmaceutical sector is becoming more sustainable. Trends in large scale oligonucleotide synthesis involve the creation of greener synthesis protocols, minimizing the use of solvents, and adopting environmentally friendly waste management strategies.

• Service Offerings Beyond Synthesis: Large-scale oligonucleotide synthesis service providers are extending their offerings to encompass process development, analytical testing, regulatory assistance, and formulation services. This holistic approach is intended to deliver end-to-end solutions to pharmaceutical firms across the drug development and commercialization process. These trends are transforming the large-scale oligonucleotide synthesis service market by facilitating more cost effective and efficient manufacturing at the scale necessary for therapeutic use, guaranteeing high product quality and regulatory compliance, encouraging sustainable practices, and providing integrated service solutions to simplify drug development.

Recent Development in the Large-Scale Oligonucleotide Synthesis Service Market

The large-scale oligonucleotide synthesis service market is growing at a rapid pace to address the increasing pipeline of oligonucleotide medicines.

• Dramatic Capacity Building by CDMOs: CDMOs are heavily investing in large scale oligonucleotide synthesis capacity additions, such as the construction of new facilities and installing additional synthesis trains, to meet the projected surge in clinical and commercial supply demand.

• Implementation of Sophisticated Analytical Methods for Quality Control: To guarantee the quality and purity of large batches of oligonucleotides, service providers are increasingly implementing sophisticated analytical methods like high resolution mass spectrometry, ion pair chromatography, and capillary gel electrophoresis for thorough characterization and impurity profiling.

• Deployment of Strong Process Analytical Technology (PAT): PAT tools are being deployed within large scale oligonucleotide production processes to continuously monitor important quality attributes, allowing for improved control of the process, decreased variability, and better product quality.

• Universal Linkers and Supports for Multimers: For convenient large scale preparation of oligonucleotides with many diverse chemical modifications, emphasis is put on creating universal linkers and solid supports adaptable to a more diverse array of modifications to curtail the demands for special material and to consolidate production.

• Greater Emphasis on GMP Manufacturing and Regulatory Compliance: With more oligonucleotide therapeutics entering late stage clinical trials and commercialization, large scale service providers are focusing heavily on compliance with stringent GMP guidelines and dealing with complex regulatory procedures across various geographies. These advances are influencing the large-scale oligonucleotide synthesis service market by augmenting accessible manufacturing capacity, improving product quality and consistency, streamlining process control, and making it easier to manufacture modified oligonucleotides, while facilitating compliance with stringent regulatory requirements for therapeutic use.

Strategic Growth Opportunities in the Large-Scale Oligonucleotide Synthesis Service Market

The large-scale oligonucleotide synthesis service market is set to experience strong growth by strategically meeting the growing demands of different applications in life sciences.

• Large Scale Commercial Manufacturing of Approved Oligonucleotide Therapeutics: The growth in approved oligonucleotide drugs provides the key opportunity for large scale synthesis service providers to win long term commercial manufacturing agreements, involving substantial production volume and quality consistency.

• Supply of Clinical Trial Material for Emerging Oligonucleotide Candidates: The robust pipeline of oligonucleotide drugs in stages of clinical development requires good quality large scale synthesis service for the manufacture of clinical trial material under GMP, providing a lucrative growth opportunity.

• Oligonucleotide Manufacturing for Gene Editing Therapies: The increasing application of synthetic guide RNAs (gRNAs) in CRISPR based gene editing therapies, both in vivo and ex vivo, presents a huge growth opportunity for mass production of these critical components.

• Large Scale Synthesis of RNAi and Antisense Oligonucleotides for Research: Academic and pharmaceutical research remain a driving force behind demand for large amounts of different types of oligonucleotides, such as siRNAs and ASOs, for preclinical research and target validation, an ongoing growth area.

• Modified Oligonucleotide Production for Diagnostic Use: The creation of sophisticated molecular diagnostics frequently demands large quantities of modified oligonucleotides for probes and primers utilized in high throughput screening and diagnostic kits, providing an opportunity for growth for large scale synthesis services with specialized expertise. These strategic growth opportunities emphasize the key position of large scale oligonucleotide synthesis services in enabling the development and commercialization of oligonucleotide therapeutics, gene editing technologies, and next-generation diagnostics, leading to huge market growth.

Large-Scale Oligonucleotide Synthesis Service Market Driver and Challenges

The large-scale oligonucleotide synthesis service market is driven by the rising clinical acceptance and commercial success of oligonucleotide therapeutics, but it also encounters severe technical, economic, and regulatory challenges. The factors responsible for driving the large-scale oligonucleotide synthesis service market include: 1. Increasing Number of Approved Oligonucleotide Therapeutics: The growing number of FDA and EMA approved oligonucleotide drugs is the key driver, generating huge demand for large scale manufacturing services to fulfill commercial supply requirements. 2. Strong Pipeline of Oligonucleotide Therapeutics in Clinical Development: Large and broad pipeline of oligonucleotide candidates across multiple stages of clinical development requires substantial demand for GMP grade oligonucleotide manufacturing for clinical trial supplies. 3. Oligonucleotide Chemistry and Modifications Advances: Improvements in new chemical modifications that improve the efficacy and stability of oligonucleotide therapeutics are fueling the demand for advanced large scale synthesis facilities for these intricate molecules. 4. Rising Investments in Nucleic Acid Drug Development: Pharmaceutical and biotechnology firms‘ increasing investments in oligonucleotide based therapy research and development directly correspond with greater demand for large scale manufacturing services. 5. Applications Beyond Therapeutics: The increasing application of large scale synthesized oligonucleotides in other fields like gene editing and sophisticated diagnostics further drives market expansion. Challenges in the large-scale oligonucleotide synthesis service market are: 1. Large Scale Synthesis Complexity and Expense: Large scale oligonucleotide synthesis, particularly for modified oligos, is technically demanding and can be extremely costly, involving specialized machinery and personnel. 2. Rigorous Quality Control and Regulatory Specifications: The production of oligonucleotides for drug applications has to be under tight GMP protocols and coping with stringent regulatory protocols in various territories, which proves difficult and expensive. 3. Optimizing Scale-Up and Yield: Optimizing scale-up from bench scale to industrial levels of oligonucleotide synthesis and maintaining high purity and yield proves a great technical hurdle that involves incessant innovation and process refinement. In short, the large-scale oligonucleotide synthesis service market is strongly fueled by the success of oligonucleotide drugs and increasing interest in nucleic acid based technologies. Nevertheless, the complexity and cost of large scale synthesis, as well as the regulatory pressures, and efficient scalability and optimization of yield, must be resolved to facilitate further growth and success in this essential market.

List of Large-Scale Oligonucleotide Synthesis Service Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies large-scale oligonucleotide synthesis service companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the large-scale oligonucleotide synthesis service companies profiled in this report include-

• Thermo Fisher Scientific

• Merck

• Azenta Life Sciences

• BBI Life Sciences

• TriLink BioTechnologies

• Aurigene Pharmaceutical Services

• Integrated DNA Technologies

• Cusabio

• Macrogen

• Synbio Technologies

Large-Scale Oligonucleotide Synthesis Service Market by Segment

The study includes a forecast for the global large-scale oligonucleotide synthesis service market by type, application, and region.

Large-Scale Oligonucleotide Synthesis Service Market by Type [Value from 2019 to 2031]:

• Common Primer Synthesis

• Modified Primer Synthesis

Large-Scale Oligonucleotide Synthesis Service Market by Application [Value from 2019 to 2031]:

• Biotech Company

• Academic Scientific Research Institution

• Others

Large-Scale Oligonucleotide Synthesis Service Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Large-Scale Oligonucleotide Synthesis Service Market

Recent trends in the large-scale oligonucleotide synthesis service market are closely associated with the growing clinical and commercial performance of oligonucleotide based medicines. This requires the generation of high volume, high quality oligonucleotides under rigorous Good Manufacturing Practice (GMP) conditions. Focus areas are on maximizing synthesis yields at scale, creating effective and affordable purification technologies, and maintaining consistent quality and regulatory compliance. The market is experiencing major investments in building up manufacturing capacities and technology enhancements to satisfy the increasing demand for therapeutic oligonucleotides worldwide.

• United States: The US is a prime location for large scale oligonucleotide synthesis services, with a robust biopharmaceutical industry and several clinical trials with oligonucleotide therapeutics. Recent advances include significant investments in the expansion of GMP manufacturing facilities by both established and new Contract Development and Manufacturing Organizations (CDMOs). Strong focus is being placed on building innovative purification technologies and maintaining strong quality control systems to comply with FDA regulations.

• China: Chinas market for large scale oligonucleotide synthesis services is growing fast, reflecting growth in its home biopharmaceutical industry. New large scale facilities with GMP capabilities have recently been established and more collaborations between local drug developers and domestic synthesis service companies are on the rise. There is an increased emphasis on the creation of cost efficient large scale synthesis processes to underpin the surging nucleic acid drug pipeline.

• Germany: Germany maintains a well established market position in the large scale oligonucleotide synthesis service market, catering to both local and foreign drug companies. Recent trends include progress in continuous flow synthesis technologies for large scale manufacturing and progress in complex analytical techniques to guarantee the quality and purity of GMP grade oligonucleotides. There is high priority placed on meeting European regulatory requirements.

• India: India‘s large scale oligonucleotide synthesis service market is in its nascent but fast developing phase. Recent trends have seen the entry of a few domestic players investing in GMP compliant large scale manufacturing facilities. Emphasis remains to offer cost effective services and serve the domestic pharma industry as well as international clients seeking economical manufacturing options.

• Japan: Japan‘s major scale oligonucleotide synthesis service industry is marked by a preoccupation with high quality and dependability that underpins its cutting edge research in RNA therapeutics. Recent trends involve investments in the production capacities of well established players and the creation of advanced synthesis and purification methods for complex modified oligonucleotides that will find therapeutic applications. There is high emphasis on compliance with rigorous Japanese regulatory standards.

Features of the Global Large-Scale Oligonucleotide Synthesis Service Market

Market Size Estimates: Large-scale oligonucleotide synthesis service market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Large-scale oligonucleotide synthesis service market size by type, application, and region in terms of value ($B). Regional Analysis: Large-scale oligonucleotide synthesis service market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the large-scale oligonucleotide synthesis service market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the large-scale oligonucleotide synthesis service market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for large-scale oligonucleotide synthesis service market? Answer: The global large-scale oligonucleotide synthesis service market is expected to grow with a CAGR of 6.8% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the large-scale oligonucleotide synthesis service market? Answer: The major drivers for this market are the rising demand for personalized medicine, the growing applications in diagnostics & therapeutics, and the increasing investments in research & development. Q3. What are the major segments for large-scale oligonucleotide synthesis service market? Answer: The future of the large-scale oligonucleotide synthesis service market looks promising with opportunities in the biotech company and academic scientific research institution markets. Q4. Who are the key large-scale oligonucleotide synthesis service market companies? Answer: Some of the key large-scale oligonucleotide synthesis service companies are as follows:

• Thermo Fisher Scientific

• Merck

• Azenta Life Sciences

• BBI Life Sciences

• TriLink BioTechnologies

• Aurigene Pharmaceutical Services

• Integrated DNA Technologies

• Cusabio

• Macrogen

• Synbio Technologies Q5. Which large-scale oligonucleotide synthesis service market segment will be the largest in future? Answer: Lucintel forecasts that, within the type category, modified primer synthesis is expected to witness higher growth over the forecast period. Q6. In large-scale oligonucleotide synthesis service market, which region is expected to be the largest in next 5 years? Answer: In terms of region, North America is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.